bluuebunny/crossref_metadata_2025_split huggingface dataset:
Differences in heart failure with preserved ejection fraction management between care providers: an international survey
Authors: Guidetti Federica , Giraldo Clara Inés Saldarriaga , Shchendrygina Anastasia , Kida Keisuke , Niederseer David , Basic Carmen , Rainer Peter P. , Załęska‐Kocięcka Marta , Ogola Elijah , Mohty Dania , Lanfranchi Giuseppina , Sari Novi Yanti , Einarsson Hafsteinn , Zurek Marzena , Ruschitzka Frank , Savarese Gianluigi , Mewton Nathan 
Published: August 2024

AbstractAimsHeart failure (HF) with preserved ejection fraction (HFpEF) is characterized by growing incidence and poor outcomes. A large majority of HFpEF patients are cared by non‐cardiologists. The availability of sodium–glucose cotransporter 2 inhibitors (SGLT2i) as recommended therapy raises the importance of prompt and accurate identification and treatment of HFpEF across diverse healthcare settings. We evaluated HFpEF management across specialties through a survey targeting cardiologists, HF specialists, and non‐cardiologists.Methods and resultsAn independent web‐based survey was distributed globally between May and July 2023. We performed a post‐hoc analysis, comparing cardiologists, HF specialists, and non‐cardiologists. A total of 1460 physicians (61% male, median age 41[34–49]) from 95 countries completed the survey; 20% were HF specialists, 65% cardiologists, and 15% non‐cardiologists. Compared with HF specialists, non‐cardiologists and cardiologists were less likely to use natriuretic peptides (p = 0.003) and HFpEF scores (p = 0.004) for diagnosis, and were also less likely to have access to or consider specific echocardiographic parameters (p < 0.001) for identifying HFpEF. Diastolic stress tests were used in less than 30% of the cases, regardless of the specialty (p = 1.12). Multidrug treatment strategies were similar across different specialties. While SGLT2i and diuretics were the preferred drugs, angiotensin receptor blockers and angiotensin receptor–neprilysin inhibitors were the least frequently prescribed in all three groups. However, when constrained to choose one drug, the proportion of physicians favoring SGLT2i varied significantly among specialties (66% HF specialists, 52% cardiologists, 51% non‐cardiologists). Additionally, 10% of non‐cardiologists and 8% of cardiologists considered beta blocker the drug of choice for HFpEF.ConclusionSignificant differences among specialty groups were observed in HFpEF management, particularly in the diagnostic work‐up. Our results highlight a substantial risk of underdiagnosis and undertreatment of HFpEF patients, especially among non‐HF specialists.
A review of the use of rice husk silica as a sustainable alternative to traditional silica sources in various applications
Authors: Taiye Mustapha Abdullateef , Hafida Wahia , Kong Fangong , Zhou Cunshan 
Published: August 2024

AbstractRice husk silica (RHS) has emerged as a sustainable alternative to traditional sources of silica in various applications, offering eco‐friendly attributes, cost‐effectiveness, and versatility. This review explores the potential of RHS as a substitute for conventional silica sources, highlighting its alignment with sustainable development objectives and its appeal to industries seeking environmental responsibility. Among the extraction methods, acid leaching is identified as yielding higher purity silica. In contrast, among the novel techniques, the hydrothermobaric process stands out for producing high purity and yielding nanosilica. Despite challenges like limited access to high‐quality rice husks and variations in silica content, RHS extraction methods show promising avenues for sustainable silica production, addressing waste management, and environmental concerns. Further development and optimization of extraction techniques are essential for widespread acceptance, with future research focusing on nanoparticle synthesis and incorporating green chemistry principles. This comprehensive review of RHS provides a valuable resource for researchers seeking to explore sustainable alternatives in their respective fields, aiming to foster adopting more sustainable practices and materials across various industries.
Sublethal Effects Induced by a Cyflumetofen Formulation on Honeybee Apis mellifera L. Workers: Assessment of Midgut, Hypopharyngeal Glands, and Fat Body Integrity
Authors: Reis Aline Beatriz , Martínez Luis Carlos , de Oliveira Mateus Soares , Souza Diego dos Santos , Gomes Davy Soares , Silva Laryssa Lemos da , Serrão José Eduardo 
Published: August 2024

Abstract
Worldwide, both cultivated and wild plants are pollinated by the honey bee, Apis mellifera. Bee numbers are declining as a result of a variety of factors, including increased pesticide use. Cyflumetofen controls pest mites in some plantations pollinated by bees, which may be contaminated with residual sublethal concentrations of this pesticide, in nectar and pollen. We evaluated the effects of a sublethal concentration of a cyflumetofen formulation on the midgut, hypopharyngeal gland, and fat body of A. mellifera workers orally exposed for 72 h or 10 days. The midgut epithelium of treated bees presented digestive cells with cytoplasm vacuoles and some cell fragmentation, indicating autophagy and cell death. After being exposed to the cyflumetofen formulation for 72 h, the midgut showed a higher injury rate than the control bees, but after 10 days, the organs had recovered. In the hypopharyngeal gland of treated bees, the end apparatus was filled with secretion, suggesting that the acaricide interferes with the secretory regulation of this gland. Histochemical tests revealed differences in the treated bees in both exposure periods in the midgut and hypopharyngeal glands. The acaricide caused cytotoxic effects on the midgut digestive cells, with apical protrusions, plasma membrane rupture, and several vacuoles in the cytoplasm, features of cell degeneration. In the hypopharyngeal glands of the treated bees, the secretory cells presented small electron-dense and large electron-lucent secretory granules. The fat body cells had no changes in comparison with the control bees. In conclusion, the cyflumetofen formulation at sublethal concentrations causes damage to the midgut and the hypopharyngeal glands of honey bee, which may compromise the functions of these organs and colony fitness. Environ Toxicol Chem 2024;43:2455–2465. © 2024 SETAC
Construction of switch information security protection system based on software‐defined networking
Authors: Huang Xueda , Zheng Kuanlei , Chen Sisi , He Zhaoren 
Published: August 2024

AbstractThe communications industry has a new, forward‐thinking architecture: software‐defined networks (SDN). The inflexible structure of conventional networks severely hinders their ability to service modern organizations. The increased adaptability and transparency of SDN‐powered networks makes them more vulnerable to security hazards like Distributed denial of service (DDoS) assaults. The switch information system introduces protection at the cost of some degree of adaptability. The information and software layers are potential entry points for DDoS assaults. The flow‐based policies frequently collide at the application layer, giving rise to safety issues. The central nervous system of the network's components is the SDN controller located at the control layer. The centrally located controller interacts with networking hardware via switches. Attacks on control devices, switches, and communication channels can cause vulnerabilities in SDN networks. The study proposes Blockchain‐SDN‐based switch information security (BC‐SDN‐SIS) to address the information security problems. SDN applications operate at the highest level of SDN controllers, facilitating the easy rollout of new network services. The suggested design uses a distributed BC approach to guarantee confidentiality, anonymity, privacy, and scalability. The proposed BC‐SDN‐SIS model increases the accuracy ratio of 97.45%, precision ratio of 98.43, recall ratio of 97.34, effectiveness ratio of 97.6%, bandwidth of 2.5 Mbps, latency rate of .04 ms and F1‐score ratio of 98.28% compared to other existing models.
A thin‐layer chromatographic study of some chemical leaf constituents in Sideritis L. sect. Empedoclia (Rafin.) Bentham (Labiatae) in Greece
Authors: Papanicolaou Kostas , Kokkini Stella 
Published: August 2024

SummaryThe genus Sideritis L. sect. Empedoclia (Rafin.) Bentham has been the subject of a thin‐layer chromatographic investigation. Leaf extracts in HCl/methanol from 54 populations of the eleven Greek taxa and from three populations of the Asiatic species S. perfoliata L. were examined. The section Empedoclia taxa may be divided chromatographically in 3 groups: 1. S. raeseri Boiss. & Heldr. – S. scardica Griseb. – S. clandestina (Chaub. & Bory) Hayek, 2. S. euboea Heldr. – S. syriaca L., 3. S. athoa Papanic. & Kokkini – S. perfoliata L. – S. sipylea Boiss. An overlapping variation occurs in the chromatographic pattern of the following pairs of taxa: 1. S. raeseri Boiss. & Heldr. ssp. raeseri – S. raeseri Boiss. & Heldr. ssp. attica (Heldr.) Papanic. & Kokkini, 2. S. raeseri Boiss & Heldr. ssp. florida (Boiss. & Heldr.) Papanic. & Kokkini – S. raeseri Boiss. & Heldr. ssp. attica (Heldr.) Papanic. & Kokkini, 3. S. scardica Griseb. ssp. scardica – S. raeseri Boiss. & Heldr. ssp. raeseri, 4. S. raeseri Boiss. & Heldr. ssp. florigda (Boiss. & Heldr.) Papanic. & Kokkini – S. scardica Griseb. ssp. longibracteata Papanic. & Kokkini, 5. S. scardica Griseb. ssp. longibracteata Papanic. & Kokkini – S. clandestina (Chaub. & Bory) Hayek ssp. clandestina.
Neue Ergebnisse und kritische Betrachtungen zur Flora Griechenlands
Authors: Voliotis Dimitrios 
Published: August 2024

ZusammenfassungEin Beitrag zur Kenntnis einiger neuer, endemischer, ± seltener oder sonstig interessanter kritischer Taxa wird vorgelegt. Eine für die Wissenschaft neue Sippe (Saxifraga taygetea (Boiss. & Heldr.) Maire & Petitmengin ssp. chelmea ssp. nov.) und zwei in Griechenland sehr seltene Arten (Melampyrum heracleoticum Boiss. & Orph. in Boiss. und Odontites lutea (L.) Clairv.), eine relativ seltene Unterart (Trachelium jacquinii (Sieber) Boiss. ssp. rumelianum (Hampe) Tutin), sowie von 4 Arten sechs neue Standorte (Circaea lutetiana L., Parnassia palustris L., Ranunculus ophioglossifolius Vill. und R. psilostachys Griseb.) und ein neuer Fundort der Art Geum coccineum Sibth. & Sm. werden beschrieben. Die Verbreitung der Sippen wird diskutiert. Die Vorkommen von Saxifraga taygetea ssp. chelmea, Melampyrum heracleoticum, Odontites lutea, Trachelium jacquinii ssp. rumelianum und Geum coccineum in Griechenland werden in einer Punktkarte dargestellt; damit sind die súdlichsten Arealgrenzen dieser Sippen auf der Balkanhalbinsel bzw. in SO‐Europa genauer erfaßt als dies bisher der Fall war.
Application of the names Cardamine acris, C. dentata. C. scutata and C. trifida
Authors: Khatri K. S. 
Published: August 2024

SummaryNomenclatural history of four species of the genus Cardamine L. of the family Cruciferae Juss. (= Brassicaceae Brunett.) has been reviewed. Out of these, C. acris Griskb., C. dentata Schult., C. scutata Thunb, are from Sect. Cardamine and C. trifida (Lam. ex Poir.) B. M. G. Jones is from Sect. Sphaerotorrhiza O. E. Schulz. For each species, possible synonyms are included to clarify the nomenclatural problems. Thus, on the basis of taxonomic history and the “International Code of Botanical Nomenclature” for each the species the first valid legitimate bionom, has been reinstated and two comb, nov. have been suggested for two distinct infra‐specific taxa of C. dentata Schult.
Numerical chemotaxonomy of Amherstieae (Caesalpinioideae)
Authors: Nageshwar G. , Radhakrishnaiah M. , Narayana L. L. 
Published: August 2024

SummaryThe distribution pattern of different secondary metabolites in ten taxa of Amherstieae (Caesalpinioideae) is studied. The synthetic numerical quantification of the chemical data provide a circumstantial evidence for the heterogenity of the tribe and the accompanying polygons depict the poor affinity at a glance. Of all the taxa, Intsia seems to be an uneasy tribe‐male. A key is provided for the identification of the taxa studied, on the basis of some chemical characters.
Ontogeny of normal and traumatic gum‐resin ducts in Ailanthus excelsa Roxb.
Authors: Venkaiah K. 
Published: August 2024

SummaryOntogeny of normal and traumatic gum‐resin ducts was studied in Ailanthus excelsa Roxb. Normal gum‐resin ducts develop schizogenously in the pith of the stem. Mechanical injury to the vascular cambium induced formation of traumatic gum‐resin ducts schizo‐lysigenously in the inner secondary phloem and sapwood. The duct system is discontinuous in the pith but it is continuous tangentially in inner secondary phloem and sapwood of stem.
First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of DS‐7011a, an Anti‐TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Authors: Senaldi Giorgio , Mohan Aparna , Zhang Li , Tanaka Jun , Lin Yong , Pandya Grishma , Grossman Sindee , Urbina Sarah , Reynolds Steven H. , Hand Alan H. 
Published: August 2024

AbstractToll‐like receptor (TLR)7 is a pattern recognition receptor that critically contributes to the pathogenesis of systemic lupus erythematosus (SLE). DS‐7011a is an anti‐TLR7 monoclonal antibody that prevents TLR7 from signaling. The aim of this first‐in‐human, double‐blind, randomized, and placebo‐controlled study was to evaluate the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of single ascending intravenous (IV) and subcutaneous (SC) doses of DS‐7011a in healthy subjects (HS) (NCT05203692). On day 1, 80 HS received DS‐7011a or placebo 6:2 in 10 cohorts (7 treated IV and 3 SC) of 8 each and were followed for 8 weeks until day 57. Safety was evaluated by recording treatment‐emergent adverse events (TEAEs), pharmacokinetics by measuring plasma DS‐7011a, immunogenicity by measuring plasma anti‐drug antibodies (ADAs), and pharmacodynamics by evaluating the suppression of interleukin‐6 production ex vivo in whole blood. DS‐7011a was safe and well tolerated across all cohorts. TEAEs were mostly mild in severity and not drug‐related. DS‐7011a exposure increased with the dose but was not dose proportional, as the elimination of lower doses was accelerated by target‐mediated drug disposition. Terminal half‐life was about 15‐17 days and Tmax upon SC administration was about 5 days. DS‐7011a induced ADAs in about half of HS but with no impact on clinical findings and pharmacokinetics. Pharmacodynamic (PD) response also increased with the dose and at the higher doses was of large extent (>90%), early onset, and lasting duration. DS‐7011a showed favorable safety, pharmacokinetics, immunogenicity, and PD properties that support its development for the treatment of SLE.
Disparities in postdischarge follow‐up and risk of readmission between Medicaid and privately insured patients
Authors: Boggs Elizabeth , Misky Gregory , Scarbro Sharon , Gritz Mark , Tipirneni Renuka , Lindrooth Richard 
Published: August 2024

AbstractBackgroundStudies have identified higher risk of readmission for patients with Medicaid compared to those with private insurance. Postdischarge follow‐up is utilized as an intervention to reduce readmissions in the Medicare population, but it is unclear whether follow‐up reduces risk of readmission for patients with Medicaid.ObjectiveTo assess whether follow‐up within 30 days of discharge reduces risk of readmission and mitigates readmission disparities based upon insurance status.MethodsThis retrospective cohort study used Cox proportional hazard and competing risk models to estimate associations between sociodemographic and clinical characteristics, follow‐up, and readmission.We analyzed data from 4281 patients aged 21–64 years with Medicaid or private insurance who were hospitalized from January 2017 to December 2019 for one of five conditions associated with high risk of readmission.Outpatient follow‐up within 30 days of discharge and 30‐day all‐cause readmission were outcomes.ResultsOverall risk of readmission was similar for Medicaid and privately insured patients in this cohort (13.7% and 14.5%, respectively). Patients with Medicaid were 23% points less likely to complete outpatient follow‐up within 30 days compared to patients with private insurance (p < .001). However, outpatient follow‐up before readmission within 30 days of discharge was not associated with a significant difference in readmission rate (hazard ratio: 1.10, 95% confidence interval: 0.91–1.32) in the overall sample or in analysis stratified by payer.ConclusionsWe found similar rates of readmission for Medicaid and privately insured patients despite significant disparities in postdischarge follow‐up. Timely follow‐up care alone may not be sufficient as an intervention to reduce readmissions.
Good 5‐year results and a low redislocation rate using an à la carte treatment algorithm for patellofemoral instability in patients with severe trochlea dysplasia
Authors: Dippmann Christian , Lavard Peter , Kourakis Anette Holm , Siersma Volkert , Hansen Philip , Talibi Monica , Krogsgaard Michael Rindom 
Published: August 2024

AbstractPurposeTrochlear dysplasia is a major risk factor for recurrent patellar instability, reduced quality of life and osteoarthritis of the patellofemoral joint. Patellar instability in patients with trochlear dysplasia can be treated by trochleoplasty, usually in combination with medial patellofemoral ligament reconstruction (MPFL‐R). An à la carte treatment algorithm, which also addresses patella alta, lateralisation of the tibial tuberosity and valgus or torsional malalignment when present has been standard in one clinic for treatment of patellar instability patients since 2009, based on the hypothesis that it results in optimal subjective and clinical outcome, normalisation of the lateral trochlea inclination (LTI) angle and a low rate of patellar redislocation.MethodsThis prospective study reports the 5‐year results for consecutive patients with high‐grade trochlea dysplasia operated according to the algorithm 2010–2017, evaluated preoperatively and 1, 2 and 5 years postoperatively. Clinical information on previous surgery and postoperative patellar stability, range‐of‐motion (ROM) and subsequent surgery were registered. Subjective outcome was evaluated by four patient‐reported outcome measures (PROMs): Kujala, Lysholm, International Knee Documentation Committee and Knee injury and Osteoarthritis Outcome Score. The LTI angle was measured pre‐ and postoperatively on magnetic resonance imaging scans.ResultsThere were 131 patients (87 females) with a median age of 22 years (range: 14–38). All had a trochleoplasty and an MPFL‐R. Additional procedures (tibial tuberosity medialisation/distalisation and/or femoral/tibial osteotomy) were performed in 52%. All PROM scores improved from preoperatively to 1‐year follow‐up with further improvement at 2 and 5 years after surgery (p < 0.05). Three patients (2%) had a traumatic patellar dislocation 9, 12 and 24 months postoperatively and 38% underwent subsequent surgery (hardware removal, arthroscopically assisted brisement force, knee arthroscopy). A normalisation of the LTI angle (≥11°) was achieved in 76%.ConclusionsTreatment according to the à la carte algorithm for patients with patellar instability and high‐grade trochlear dysplasia resulted in significant clinical and subjective improvement in all PROM scores and a very low redislocation rate (2%) 5 years after surgery.Level of EvidenceLevel II.
Influence of Single Nucleotide Polymorphisms on CRS Outcomes: A Preliminary Observational Study
Authors: Maniaci Antonino , Bonacci Paolo , Stefani Stefania , Cocuzza Salvatore , Merlino Federico , Saibene Alberto Maria , Sangiorgio Giuseppe , Maza‐Solano Juan , Lechien Jerome R. , La Mantia Ignazio , Musso Nicolo' 
Published: August 2024

Objective(s)To conduct a preliminary investigation into the relationship between specific SNP variants, type II inflammation, and the effectiveness of dupilumab therapy and surgery in patients with CRS.MethodsIn this prospective study, 48 subjects were enrolled, comprising 32 CRS patients and 16 healthy controls. The CRS patients were subjected to either dupilumab therapy or endoscopic surgery according to EPOS guidelines. SNP variants were identified using the TaqMan SNP genotyping technique. The identified SNP profiles were compared between the control group and CRS patients, and their potential influence on treatment outcomes was evaluated. Treatment responses were assessed based on symptom scores, such as SS‐I, SNOT‐22, disease progression using the NPS findings, and SNP profiles at a 6‐month follow‐up. The primary measures included the Nasal Polyp Score, Smell Identification Test (SIT) score, and SNOT‐22 outcomes.ResultsDupilumab therapy and surgery significantly decreased NPS, with the last showing superior results. However, dupilumab therapy resulted in a significantly improved SIT score. Significant differences were observed in SNP profiles, particularly with rs1800629 (TNFA), rs2856838 (IL1a), rs17561 (IL1a), and rs1805011 (IL4R). In particular, the expression of rs2856838 and rs1805011 variants in the dupilumab group was associated with significantly better SIT and SNOT‐22 outcomes than non‐expressors. Also, the surgery group patients expressing the rs2856838 variant reported significant improvements in SNOT‐22 scores.ConclusionThese preliminary findings suggest that SNP genotypes may guide personalized treatment strategies for CRS. Further larger prospective studies are required to confirm these initial observations.Level of Evidence2 Laryngoscope, 135:570–578, 2025
Head and neck cancer: pathogenesis and targeted therapy
Authors: Liu Yan , Zhang Nannan , Wen Yi , Wen Jiaolin 
Published: August 2024

AbstractHead and neck cancer (HNC) is a highly aggressive type of tumor characterized by delayed diagnosis, recurrence, metastasis, relapse, and drug resistance. The occurrence of HNC were associated with smoking, alcohol abuse (or both), human papillomavirus infection, and complex genetic and epigenetic predisposition. Currently, surgery and radiotherapy are the standard treatments for most patients with early‐stage HNC. For recurrent or metastatic (R/M) HNC, the first‐line treatment is platinum‐based chemotherapy combined with the antiepidermal growth factor receptor drug cetuximab, when resurgery and radiation therapy are not an option. However, curing HNC remains challenging, especially in cases with metastasis. In this review, we summarize the pathogenesis of HNC, including genetic and epigenetic changes, abnormal signaling pathways, and immune regulation mechanisms, along with all potential therapeutic strategies such as molecular targeted therapy, immunotherapy, gene therapy, epigenetic modifications, and combination therapies. Recent preclinical and clinical studies that may offer therapeutic strategies for future research on HNC are also discussed. Additionally, new targets and treatment methods, including antibody–drug conjugates, photodynamic therapy, radionuclide therapy, and mRNA vaccines, have shown promising results in clinical trials, offering new prospects for the treatment of HNC.